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The efficacy and toxicity of radionuclide therapy are believed to be directly related to the radiation doses
received by target tissues; however, nuclear medicine therapy continues to be based primarily on the
administration of empirical activities to patients and less frequently on the use of internal dosimetry for
individual therapeutic planning. This review aimed to critically describe the techniques and clinical evidence of
dosimetry as a tool for therapeutic planning and the main limitations to its implementation in clinical practice.
The present article is a nonsystematic review of voxel-based dosimetry. Clinical evidence pointing to a
correlation between the radiation dose and therapeutic response in various diseases, such as thyroid carcinoma,
neuroendocrine tumors and prostate cancer, is reviewed. Its limitations include technical aspects related to
image acquisition and processing and the lack of randomized clinical trials demonstrating the impact of
dosimetry on patient therapy. A more widespread use of dosimetry in therapeutic planning involves the
development of user-friendly dosimetric protocols and confirmation that dose estimation implies good efficacy
and low treatment-related toxicity.
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’ INTRODUCTION
Radionuclide therapy was initially proposed in the mid-
1940s and uses radioactive iodine isotopes to control hyper-
thyroidism or to destroy differentiated thyroid cancer cells (1).
The use of iodine-131 for thyroid diseases still corresponds to
the most frequent radionuclide therapy in nuclear medicine,
although significant expansion of the use of new radio-
pharmaceuticals for diagnostic and therapeutic purposes in
oncology is underway. The expansion of clinical indications has
resulted from the development of new radiolabeled com-
pounds as well as evidence of the response to therapy in
randomized clinical trials, such as the use of somatostatin-
lutetium-177 analogs for neuroendocrine tumors (2) and radio-
223 for bone metastases of prostate carcinoma (3).
Although both nuclear medicine and radiotherapy use
ionizing radiation for therapeutic purposes, it should be
emphasized that radiopharmaceuticals administered in
nuclear medicine are nonsealed sources, with wide distribu-
tion and metabolic interactions in the patient. Radiopharma-
ceuticals consist of a chemical compound (drug) combined
with a radioactive isotope and exhibit extensive biological
exchange in the organism due to their variable affinity for
binding sites and excretion pathways. This pharmacokinetic
behavior leads to the difficulty of accurately establishing the
residence time of the radiopharmaceutical in each organ or
tissue and makes it difficult to precisely determine the dose
of radiation absorbed at the site. This is one of the main
reasons that the planning of radionuclide therapy is usually
based on the amount of radioactive substance (activity),
expressed in Becquerel (1 Bq=1 disintegration per second) or
Curie (1 Ci=3.7 1010 Bq), administered to the patient rather
than the radiation absorbed dose, as measured by the energy
deposited on a given mass of tissue, expressed in Gray units
(1 Gy=1 joule/kg).
The efficacy and toxicity of radionuclide therapy are
believed to be more directly related to radiation doses in
target tissues and healthy tissues than to the administered
radiopharmaceutical activity. However, despite recent advances
in the field of internal dosimetry, with a good estimation of
radiation doses, the method still has limited applications in
therapeutic planning.
This review aimed to critically describe the techniques and
clinical evidence of internal dosimetry as a therapeutic plan-
ning tool and the main limitations found in its implementa-
tion in clinical practice.DOI: 10.6061/clinics/2019/e835
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Basics and methods of internal dosimetry
The radionuclides most commonly used in therapy emit
particles with a low penetration range and high linear energy
transfer (LET), leading to high ionization in the uptake site
(4). Under some conditions, they also emit gamma radiation,
which has high penetration and can be detected externally
in the patient’s body, allowing the imaging of the radio-
pharmaceutical biodistribution (Table 1). Radioisotope ima-
ging obtained by planar scintigraphy, single-photon emission
computed tomography (SPECT) and positron emission
tomography (PET) scans is essential for determining the
dose of radiation in a specific tumor or organ. Measurements
of blood samples or whole-body detectors can also be used
to estimate the dose of radiation in the bone marrow (5) but
are less useful for the dosimetry of localized structures, such
as tumors.
The image acquired for dosimetry purposes should be
quantitative, going beyond simple image registration for
the visual identification of normal and pathological struc-
tures. It is necessary to construct a map that reflects the actual
activity in each structure or organ in real time, delimited by
the regions of interest (ROIs) in planar imaging or the volumes
of interest (VOIs) in SPECT or PET (6).
Quantitative data are more directly obtained in PET
studies, in which the information is usually stored in units
of activity per volume (Bq/mL), since the necessary correc-
tions for quantification are incorporated into image acquisi-
tion and processing. However, a large number of studies in
therapy describe the planar or SPECT imaging of gamma
radiation, which requires several corrections to be adequately
quantified (6,7). Among the required corrections, the follow-
ing are highlighted:
Attenuation correction. Radiation from deep structures
in the body is partially blocked / attenuated before reaching
the detector. To retrieve this information, a correction factor
is applied based on the X-ray (CT) available in PET/CT and
SPECT/CT hybrid equipment. The CT provides a map of
attenuation values for each voxel, expressed in Hounsfield
units (HU).
Scatter correction. Radiation from an organ may not
be blocked but is diverted from its initial trajectory by
interacting with body tissues. The radiation, when diverted,
loses part of its energy, and this energy difference makes
it possible to make specific acquisitions to correct for the
scattering, with the use of multiple energy windows.
Compensation of the collimator-detector response.
events that lead to the loss of image quality upon interaction
with the radiation detector, such as those arising from septal
penetration and attenuation in the collimator, can be determined
directly or by Monte Carlo simulation (point spread function).
Its compensation during iterative image reconstruction allows
resolution recovery in the SPECT images.
Calibration of the equipment. the acquisition of
images from a phantom with known activity, including all
the previously mentioned corrections, allows the relation
between the number of counts detected in the image and the
real activity to be established. This relationship can then be
used to quantify patient images obtained with the same
acquisition and processing parameters.
Dosimetry methods can be applied to estimate the doses
of radiation received by the organs based on the detection
and quantification of activity in a series of images acquired at
different intervals after the administration of a radiophar-
maceutical. The most widely used and validated method of
internal dosimetry is the medical internal radiation dose
(MIRD), idealized by the Internal Dosimetry Committee of
the United States Society of Nuclear Medicine (SNM) and
later adopted by the International Commission on Radi-
ological Protection (ICRP) and the International Atomic
Energy Agency (IAEA) (8). A graph of activity as a function
of time can be constructed for a given organ. The area under
the curve gives the total accumulated activity (Ã) in the
organ over time (Figure 1). The division of Ã by the total
amount of activity administered to the patient (Ao) results in
the residence time of the radiopharmaceutical. These data,
together with the patient characteristics (sex, age, and body
weight), are applied in mathematical formulas to estimate
the radiation absorbed dose per administered activity (Gy/
Bq). The mathematical formalism employed by the MIRD
can be summarized by the equation below:
D Gyð Þ¼ ~A X S;
where D and Ã represent the radiation absorbed dose and
accumulated activity in the organ, respectively, and S repre-
sents the dose constant that results from self-irradiation due to
Figure 1 - Time-activity curve: activity was quantified in
consecutive images after drawing a region of interest (ROI) in
the organ. The area under the curve corresponds to the
accumulated activity (A˜), reflecting the total number of atoms
that disintegrated in the region.
Table 1 - Physical characteristics of commonly used radionuclides in therapy.
Radionuclide Physical half-life (days) Particle energy Beta (keV) Maximal range (mm)
Iodine-131 8.0 610 2.0
Lutetium-177 6.7 496 1.6
Yttrium-90 2.7 2,290 11.9
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the accumulation of a specific radioisotope in a given organ
added to the irradiation due to the accumulation of radio-
isotopes in other organs that affect the organ under study.
In addition to the residence time of the radiopharmaceu-
tical in each organ, the S factor of the formula takes into
account the physical characteristics of the radiation emitted by
a specific radioisotope and the distance and geometric relation
between organs. The geometry and its implications for
interorgan irradiation are defined by the use of human body
reference models. Thus, internal dosimetry using the MIRD
formalism is based on the kinetics of accumulation and elimi-
nation of the radiopharmaceutical, which can be estimated
through the quantification of images and geometric models
of the human body. Although it is suitable for estimating the
dose and population risk of probabilistic (stochastic) effects
in which the absorbed radiation dose (Gray) is converted to
equivalent and effective doses (expressed in Sieverts; 1 Sv=1
Gy for gamma or beta particles), the MIRD formalism is not
always adequate for the estimation of the doses of radiation
absorbed in a specific patient, since it does not consider
individual variations in biodistribution and geometry.
In the context of the need for individualized dosimetry
methods, the expansion of tomographic hybrid equipment –
PET/CT and SPECT/CT – allowed the development of
dosimetry methods, especially voxel-based dosimetry, based
on real patient volumetric data (9,10). The concept of voxel
dosimetry has already been incorporated into current MIRD
publications for therapeutic planning (11,12). A voxel is the
smallest element of a three-dimensional image, equivalent to a
pixel in a planar image. Attenuation, scattering, resolu-
tion and calibration corrections are still necessary and even
more critical for the quantification of a voxel to voxel activity.
In addition, it is necessary to carefully adjust the positioning
between the images acquired at different times so that a voxel
of the same xyz coordinate corresponds to the same anato-
mical structure in consecutive images, and thus, the voxel
cumulated activity (Ã) can be calculated.
Voxel-based dosimetry follows a different sequence from
the traditional method, since the initial delimitation of the
organs is not necessary to quantify the cumulative activity
(Ã) in a given organ. The first step is to adjust the spatial
position of all sequential images so that a voxel of the same
xyz coordinate always matches the same structure. The time-
activity curve of each voxel xyz throughout the patient’s body
is then obtained, and the integration of these curves results
in a tridimensional matrix that represents each voxel
́
s Ã.
The image representing the spatial distribution of the
parameter Ã is used to estimate the radiation absorbed
(Gy) in each voxel of the patient’s body (Figure 2). Only
at the end of this phase will the VOIs over the dose image
be defined to estimate the radiation absorbed in a given
organ or tumor.
Figure 2 - Sequential PET or SPECT images are coregistered so that a voxel of the same xyz coordinate always corresponds to the same
structure. The calibration factor allows the transformation of counts in radioactivity (MBq). A parametric image of accumulated activity
A˜ (MBq.h) is obtained from the integral of activity through time in each voxel. The energy deposited in each voxel is calculated based
on the local energy deposition (LED) or dose point kernel (DPK) and results in the radiation absorbed dose parametric image (Gy).
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The conversion from the parametric image ‘‘Ã’’ to the
parametric image ‘‘Gy’’ is achieved by considering that the
energy emitted by the radionuclide will either all be deposi-
ted in the voxel itself (local energy deposition – LED) or
also be deposited in neighbor voxels with homogeneous
attenuation (dose point kernel – DPK). Alternatively, Monte
Carlo methods allow a more complete simulation of energy
deposition, considering the random nature of particle inter-
actions and tissue heterogeneity, despite the greater com-
plexity and demand for resources and time (13). Both DPK
and Monte Carlo simulations consider that, as in the
conventional MIRD formalism, the radiation dose in a voxel
will result from its self-irradiation added to the irradiation
from neighboring voxels.
Clinical evidence of internal dosimetry in
radionuclide therapy planning
Differentiated thyroid carcinoma (DTC). Radioiodine
therapy is the most frequent therapy in nuclear medicine
based on the expression of the sodium-iodine symporter
(NIS) in differentiated thyroid carcinoma cells. Although
radioiodine therapy is the most studied situation from the
perspective of dosimetry, therapy is still usually performed
based on the administered iodine-131 activity. Recent recom-
mendations suggest the use of the administered activity of
30 to 100 mCi for thyroid remnant ablation, 100 to 150 mCi
for adjuvant therapy, and 100 to 200 mCi for the treatment of
a residual tumor or metastatic disease after surgery (14).
Specifically, in the therapy of metastatic disease, there is a
good response to the treatment of pulmonary micrometas-
tases, with a low chance of a complete response in patients
with macronodular pulmonary metastases or bone metas-
tases. Among the main evidence is the comparison of sur-
vival in historical series (15) and retrospective studies that
show a reduction in survival in patients with late indications
of radioiodine therapy (16).
Dosimetric measures aimed at reducing treatment toxi-
city were proposed in the 1960s by restricting the bone
marrow dose below 2 Gy and whole-body retention 48 h
o120 mCi (o80 mCi in cases of diffuse lung uptake) (17).
The administration of activities greater than or equal to 200
mCi results in a bone marrow dose 42 Gy in 11 to 22% of
patients (18), which is the reason for limiting the treatment
to 150 mCi in elderly patients (over 70 years old) for whom
dosimetry is not performed (14). Although some studies
show an increase in the complete response using a safe maxi-
mum dose compared to treatment with empirical activities
in patients with metastatic or locally advanced disease (19),
these data have not been confirmed in studies with a large
series comparing the use of fixed 100 mCi activity (Gustave-
Roussy – France) with the safe maximum dose (Memorial
Sloan Kettering – USA) (20).
The main evidence of a relationship between tumor dosi-
metry and the response to complete decongestive therapy
(CDT) with iodine-131 was obtained in Maxon’s studies,
in which a good probability of thyroid ablation was obser-
ved with doses 4300 Gy and metastases with doses 485
Gy (21,22). A better response in lymph node metastases
with doses 4100 Gy was also reported in a concurrent
study (23). A more recent study in which dosimetry was
performed using PET with iodine-124 confirmed good
responses in thyroid remnant ablation with doses above
300 Gy and 85 Gy in metastases, despite the limitations for
dose determination in small volume lesions (24). A good
correlation between the dose and remnant ablation has
also been described with SPECT-based dosimetry (25).
Although it is the first and most widely used modality for
radionuclide therapy, there is a lack of randomized clinical
trials of radioiodine therapy in CDT.
Neuroblastoma and malignant pheochromocytoma.
Iodine-131 meta-iodobenzylguanidine (131I-MIBG) therapy
is based on the uptake of adrenaline analogous to tumors
of neuroectodermal origin that maintain amine reuptake
mechanisms. Approximately 90% of neuroblastomas are
avid and amenable to treatment with MIBG, with response
rates above 30% in patients with refractory or recurrent
neuroblastoma (26), as well as increasing indications for the
induction or consolidation of therapy (27).
Usually, the therapy is prescribed empirically, with fixed
or weight-adjusted activities (e.g., 200 mCi or 10 to 12 mCi/
kg). The limiting toxicity may result from bone marrow
irradiation, which usually ranges from 0.5 to 6 Gy, and bone
marrow support or transplant is required in patients treated
with high activities, which may reach 18 mCi or up to 50
mCi/kg (28). Two cycles of therapy, the first fixed (12 mCi/
kg) and the second set by dosimetry to achieve a whole-body
radiation dose of 4 Gy, is an option adopted by some centers
with great success (27). Whole-body dosimetry is closely
related to the bone marrow dose, and both are commonly
used dosimetric parameters. Tumor dosimetry is rarely per-
formed and is still considered a relatively complex proce-
dure, requiring repeated images and measurements (29).
Whole-body and bone marrow doses following 131I-MIBG
therapy have been estimated, with reasonable safety and
reproducibility (30), and in patients with neuroblastoma,
the dose of whole-body radiation is correlated with the
administered activity/kg; however, there is no clear correla-
tion between the dose of radiation and the response to
therapy or toxicity (28).
Neuroendocrine tumors. Somatostatin analogs labeled
with beta particle emitter radionuclides, such as 177Lu-
DOTATATE, are employed for the treatment of neuroendocrine
tumors, which express somatostatin receptors in their cell
membranes. The treatment is usually based on activity
(4 cycles of 200 mCi), and its efficacy for progressing inoper-
able neuroendocrine tumors was demonstrated in a recent
randomized clinical trial (2). The limiting toxicity is due to the
radiation dose in the kidneys and bone marrow. Renal dosi-
metry may be used to adjust the administered activity in the
last cycle of therapy. Although studies suggest a moderate
correlation between dosimetry and the tumor response (31) and
renal toxicity (32), there is still variability in the dose estimates
according to the protocols of acquisition and image processing,
which adds to the interpatient and radiopharmaceutical
variation as well as variations in the dose estimate between
cycles and between local or whole kidneys (33,34).
Yttrium-90 microsphere therapy for hepatic lesions.
The efficacy of the radioembolization of hepatic lesions
with 90Y particles has been demonstrated in clinical trials
on primary liver tumors (hepatocarcinoma – HCC) (35)
and metastatic tumors (36). Planar scintigraphy or SPECT
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performed after the intra-arterial injection of 99mTc-MAA can
be used to evaluate the biodistribution of the 90Y micro-
spheres used in radioembolization, mainly in the definition
of a pulmonary shunt or as an adjunct to angiography in the
evaluation of a shunt to the digestive tract (37,38).
From a technical point of view, therapy with micro-
spheres is possibly the simplest application of voxel-based
dosimetry, since the radiopharmaceutical is retained in
the tissue immediately after intra-arterial administration,
without significant mechanisms of elimination other than
physical decay (38). In this way, only one image is necessary,
and there is no need to acquire and coregister a series of
images. More frequently, voxel-based dosimetry is based on
a SPECT/CT scan after the administration of a technetium-
99m-labeled macroaggregate of albumin (99mTc-MAA). Brak-
ing radiation (Bremsstrahlung) or the very limited positron
emission of yttrium-90 can also be used for dosimetric
studies after the procedure.
However, even with great technical simplicity, some
factors of error or confusion should be noted (39), such as
dose variation according to the tumor volume determination
method (CT includes necrotic/hypoperfused areas and
results in a greater volume and lower dose estimation com-
pared to SPECT) and variation in the number and particle
sizes of the MAA compared to 90Y-microspheres.
Retrospective studies have shown that an estimated
dose 4200-280 Gy in a primary or secondary liver tumor is
associated with a high objective response, overall survival
and disease-free survival (39,40). Although the estimated
radiation dose is correlated with the tumor response and
survival, the role of dosimetry in planning or enhancing
therapy is still unclear. There is also no clear dosimetric
determination of limits for irradiation to the liver or lung.
Radium-223 therapy for prostate carcinoma. Radium-
223 (223Ra) is a radioisotope with high uptake in areas
of bone remodeling, such as metastatic sites. The efficacy
of 223Ra therapy was recently confirmed in a randomized
clinical trial of patients with castration-resistant prostate
cancer presenting with bone metastases and no visceral
involvement (3). Therapy is based on a constant activity
(50 kBq/kg) administered every 4 weeks for a total of
6 cycles. The radiation dose is approximately 10 times higher
in the cortical bone than in the bone marrow, which justifies
the low prevalence of bone marrow toxicity by the treatment
(41,42). There is no clear correlation between the tumor
radiation dose and the response to 223Ra therapy. Dosimetry
is complicated in this scenario because 223Ra is an alpha
particle emitter with high ionization in a very short trajec-
tory. Therefore, precise knowledge of its location is essential
for dose estimation. However, there is almost no emission
of detectable gamma radiation, which makes it difficult to
obtain images to determine the radionuclide distribution
and kinetics.
Limitations and challenges of clinical dosimetry
In addition to the methodological difficulties encounte-
red in quantitative studies and the application of clinical
dosimetry in the estimation of the dose of radiation received
by the tissues, other limitations of technical and clinical
nature contribute to the reduced number of dosimetric
therapeutic plans.
Technical limitations. Several difficulties associated
with the dosimetry method, including the need for careful
correction of the attenuation, scattering and resolution of
images, have been previously addressed. Even optimized
images suffer from limited resolution, which leads to partial
volume effects (spill-in and spill-out) and ‘‘blurring’’ of the
structure outline. Image resolution can be defined as the
ability of the system to distinguish and register two sources
as distinct, and a limitation of this capability leads to
imprecision in the positioning of the radiation source. If there
is inaccuracy in the location of the radiopharmaceutical
uptake area, the same imprecision will be present in the
estimation of the radiation dose. For this reason, radiation
dose estimation in lesions less than twice the resolution of the
imaging system (i.e., approximately 2 cm in a SPECT study)
should be considered underestimated (43). Additionally, the
resolution of the anatomical image (CT) can be a limiting
factor, and in situations where the volume or mass of the
biological structure cannot be accurately measured (e.g., in
pulmonary micrometastases, bone metastases, and subcenti-
metric lymph nodes), dose estimation may also be proble-
matic, since the volume or mass that will receive the energy
of the incident radiation is not accurately defined.
In addition to the uncertainty in the positioning of the
radioactive event or the irradiated structure (due to the
limited resolution of nuclear medicine and even of CT), other
uncertainties present in PET or SPECT images will also be
observed in dosimetry. For planning purposes, SPECTor PET
should ideally be obtained before therapy during a diag-
nostic study. The small activities used in diagnostic studies
imply low count rates and high statistical fluctuation in the
number of counts per voxel and thus should be considered.
This noise will propagate throughout all dosimetric proce-
dures and may be erroneously assumed as a sign of dose
heterogeneity. The use of dose histograms as markers of
dose heterogeneity (44), implying small tumor responses
(similar to the equivalent uniform dose – EUD – concept in
radiotherapy), may be a misleading parameter in nuclear
medicine. Additionally, the concept of the biological effective
dose (BED) used in radiotherapy is less well defined in nuclear
medicine due to the incomplete knowledge of biological
responses in a low, continuous and decreasing dose rate.
Regarding reproducibility, it is difficult to state that the
pharmacokinetic behavior observed in the therapy will be the
same as that in the diagnostic study performed with ‘‘tracer’’
activities, since the physiological conditions of the organism
can vary between two moments (e.g., TSH level in radioiodine
therapy, renal function, and hydration) (45). In cases where
internal dosimetry is performed to establish the dose
resulting from the therapeutic cycle itself, with high activity
and low noise in the images, dosimetric data are useful for
the eventual planning of subsequent therapeutic cycles.
Again, there is no guarantee that the pharmacokinetic
behavior will be the same in each cycle, and it should be
noted that tissues irradiated during the first cycle may
undergo inflammatory changes or even cell death resulting
from the treatment itself.
In addition to resolution, noise and reproducibility, it
should be noted that among the sequential images
combined to generate the parametric image of accumulated
activity (Ã), there is a possible displacement of structures
that would correspond to the same volume in the patient
(e.g., intestinal loop in different locations within the abdomen).
Overlap of the xyz coordinates of the corresponding voxels in
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the various images can be achieved by inelastic (without
image deformity) or elastic (with image deformity) coregistra-
tion of the images.
Practical limitations. In addition to the abovementioned
technical limitations, there are also practical limitations in
the implementation of dosimetry-based therapy planning.
Properly trained professionals in this field with mastery of
both dosimetry and instrumentation concepts are rare. The
training and hiring of these professionals would require
investments from the nuclear medicine service, without clear
economic returns. Outsourcing dosimetric procedures would
require the integration of external professionals into the
clinical routine through mandatory interfaces in quality
control, scheduling, acquisition and image processing.
Hybrid imaging is essential for attenuation correction
and consequently for image quantification used in voxel-
based dosimetry. Although PET/CT is typically used for PET
studies, the same does not apply to SPECT/CT, which is
still scarcely available and associated with significantly high
equipment costs. Multiple imaging time points needed for
TAC integration also compete with examination slots needed
in different clinical scenarios, such as baseline staging,
the detection of relapse, treatment monitoring, increased
costs and the impact of the procedure in a routine nuclear
medicine service.
One possible minimization of these negative effects
would be the use of simplified dosimetric estimates with
fewer images (e.g., the use of only two SPECT images for
dose estimation (33) or the association of a single SPECT
image with other planar scans (6)). This strategy allows the
use of a single SPECT volumetric image with kinetic adjust-
ment by data from previous studies (46). However, there
should be a tradeoff between simplifying procedures and
maintaining sufficient dosimetric accuracy to allow ade-
quate therapy planning.
Radiobiological limitations. When internal dosimetry
is performed using either the traditional organ-based method
or the voxel-based method, the radiation absorbed dose is
estimated in Gray units (1 Gy=1 joule/kg). However, the
deposition of a certain amount of energy in an organ or a
tissue is not the only factor related to a specific biological
effect, such as cell death. The dose rate and dose distribution
are important effect determinants in external beam radio-
therapy, but their roles in internal dosimetry are not well
understood.
Cells and tissues have the ability to repair radiation-
induced damage, and this adaptive response should be
considered in biological models. As time is required for a
biological response to develop, the dose rates and fractiona-
tion have an impact on external radiotherapy effects. The
concept of BED, which is based on the linear-quadratic model,
allows the comparison of different dose rates that would lead
to the same biological effect. However, even if the BED is a
valid parameter for external beam radiotherapy, its value has
not been clearly established in the ultralow dose rates of
continuous radiation delivered from radionuclides (47).
The spatial distribution of the radiation dose in a target can
also have a significant impact on its effects. One method used
to assess dose heterogeneity in a tumor is the dose-volume
histogram, which can be obtained in internal dosimetry
methods based on voxels. The EUD establishes the equiva-
lence of a heterogeneous dose with an evenly distributed dose
in a tumor and could, in theory, be used as a parameter in the
planning of radionuclide therapy. However, PET or SPECT
images used in voxel-based dosimetry are a limited repre-
sentation of the actual distribution of radioisotopes in the
patient’s body. The intrinsic statistical fluctuation leads to
noise and therefore the introduction of heterogeneity in the
images that does not correspond to the real distribution of the
radionuclide in the patient. On the other hand, the low spatial
resolution and partial volume effect lead to a loss of contrast
and to homogenization of the dose estimate. There are no data
available on how the heterogeneity of voxel-based dosimetry
in radionuclide therapy should be interpreted.
The field of radiobiology also seeks a better understanding
of the mechanisms related to bystander and abscopal effects
(48) (effects of radiation on nearby and on distant nonirra-
diated cells, respectively), which together with different
radiosensitivities of patients could lead to a nonlinear dose-
response relationship in radionuclide therapy. Although it
is increasingly important in the emergence of new clinical
applications of radionuclide therapy, the correct interpretation
of internal dosimetry parameters from a radiobiological point
of view is not currently available. Reliable dosimetric protocols
are a prerequisite to learn about the biological and medical
interpretations of internal dosimetry in the research setting.
Clinical limitations. In the context of a nuclear medicine
laboratory, internal dosimetry adds complexity and time to
the daily routine, with the need to implement methods that
are not fully standardized. Sequential multi-field-of-view
SPECT scans are required for the quantification of cumula-
tive activity and residence time for each organ or voxel,
ideally in two stages in the accumulation phase and at least
twice in the phase of elimination of the radiopharmaceutical
in biological organs and tissues, not necessarily adding
diagnostic information to the process (34).
Some oncological patients, especially those with advan-
ced stage disease, often suffer from pain or limited breathing
(e.g., due to ascites/pleura effusion) and may not tolerate
long imaging exams. In regions with poor public transporta-
tion, traveling to the hospital to obtain delayed images can
be challenging for patients in a reduced general condition.
The whole dosimetric process, including processing and
analysis, should be completed shortly after the last imaging
to not delay the start of treatment, an issue that may be
critical for fast growing tumors. It has not yet been clearly
demonstrated that the benefits of individual dosimetry out-
weigh these negative effects, which could be reduced using a
more straightforward approach with fewer images. The impact
of a simplified dosimetric procedure in the final results
regarding toxicity and tumor control has yet to be defined.
The incorporation of dosimetric procedures into the
clinical routine would therefore need a strong foundation to
support and justify its complexity and costs. However, as
previously mentioned, radionuclide therapy has histori-
cally been established by empirical protocols based on the
amount of activity administered to patients, and there is no
clear demonstration of its benefits in terms of the tumor
response or toxicity due to the implementation of dosi-
metric planning. Therefore, there is a vicious circle in which
the implantation of dosimetry lacks justification based on
clinical evidence, which in turn is difficult to obtain due to
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the low availability and adherence to clinical dosimetry
protocols in nuclear medicine.
Based on the opinions of the authors, among the factors
important for the clinical implementation of dosimetry, it
would be desirable to have the following available:
a) low-cost software for voxel-based dosimetry running in
already existing work stations,
b) a reduced number of images required – a minimum of one
image at the maximum activity time (Tmax) associated
with kinetic parameters or a delayed image (3 to 5x effec-
tive half-life),
c) demonstration of the relation between the dose and mea-
surable biological response, and
d) trained personnel to perform internal dosimetry.
To contribute to these goals, our research group devel-
oped a dosimetric program at the Cancer Institute of the
State of São Paulo (ICESP) in 2015/16 with the support of the
Fundacao de Amparo a Pesquisa do Estado de São Paulo
(FAPESP) in the Research Program for SUS (PPSUS process
no 2014/50091-5). The interactive software was developed to
process SPECT/CT images in the MATLAB platform (Matrix
Laboratory) with the following steps: the volumetric images
were read and coregistered in Analyze format; the image
matrix was converted to the activity matrix by voxels (MBq)
through the application of conversion factors; the activity
integral (by voxel) was calculated, resulting in a map of
accumulated activity (Ã) by voxel; the map of Ã by DPK
or LED factors was multiplied to obtain the radiation dose
map by voxel (Gy); and the parametric dose images were
reconverted to Digital Imaging and Communications in
Medicine (DICOM) format, allowing further analysis in
computer programs such as OsiriX (freeware). The devel-
oped code was renamed NMdose-VX, and the radiation dose
provided by the code was compared to other dosimetry
methods, such as thermoluminescent dosimetry (TLD) and
OLINDA/EXM software, the latter being considered the
standard method for internal dosimetry. NMdose-VX per-
formed well in comparison with the indicated methods,
allowing the use of patient images instead of idealized
anthropomorphic models (49). Currently, the NMdose-VX
code continues to be developed, with future prospects for
making it more widely available.
’ CONCLUSION
Voxel-based dosimetry allows internal dosimetry to be
individualized, with the possibility of being incorporated
into the therapeutic plan of patients. However, there are still
technical and clinical limitations that hamper its broad use in
the growing area of radionuclide therapy. Overcoming these
limitations involves the development of user-friendly dosi-
metric protocols that are not costly and easy to implement
in the clinical routine, along with the demonstration of its
clinical benefits in well-conducted studies, which should
clarify whether dosimetric therapy planning translates to
decreased toxicity and good tumor responses.
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